VanEck Biotech ETF (NASDAQ:BBH) Shares Sold by Telemus Capital LLC

Telemus Capital LLC cut its stake in VanEck Biotech ETF (NASDAQ:BBH) by 2.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,045 shares of the company’s stock after selling 75 shares during the quarter. Telemus Capital LLC’s holdings in VanEck Biotech ETF were worth $503,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in BBH. Valley Wealth Managers Inc. purchased a new position in VanEck Biotech ETF in the third quarter valued at about $2,956,000. J.P. Morgan Private Wealth Advisors LLC raised its position in VanEck Biotech ETF by 192.1% in the third quarter. J.P. Morgan Private Wealth Advisors LLC now owns 8,492 shares of the company’s stock valued at $1,322,000 after purchasing an additional 5,585 shares during the period. Raymond James Financial Services Advisors Inc. raised its position in VanEck Biotech ETF by 34.5% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 19,129 shares of the company’s stock valued at $3,162,000 after purchasing an additional 4,909 shares during the period. International Assets Investment Management LLC purchased a new position in VanEck Biotech ETF in the fourth quarter valued at about $305,000. Finally, Wealthfront Advisers LLC raised its position in VanEck Biotech ETF by 32.8% in the third quarter. Wealthfront Advisers LLC now owns 5,229 shares of the company’s stock valued at $814,000 after purchasing an additional 1,292 shares during the period. 32.05% of the stock is owned by hedge funds and other institutional investors.

VanEck Biotech ETF Stock Up 1.5 %

Shares of NASDAQ BBH opened at $154.59 on Tuesday. VanEck Biotech ETF has a 1 year low of $142.51 and a 1 year high of $171.04. The stock’s 50-day simple moving average is $162.52 and its 200-day simple moving average is $159.80.

VanEck Biotech ETF Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.